Background: Hip fracture is associated with high morbidity, mortality and economic burden worldwide. Antiresorptive medications reduce the incidence of hip fractures however prescribing of these medications remains poor. The Irish Hip Fracture database 2016 has shown that only 30% [1] of patients are discharged on antiresportive medication post hip fracture.
Methods: The hip fracture protocol was established in July 2014. We collected data on bone protection medication for patients admitted with a hip fracture to an urban teaching tertiary referral hospital and subsequently discharged between July 2016 and April 2017. Results: There were 139 patients (104 female: 35 male) admitted with a hip fracture over the nine month period. The average age was 82 yrs. Overall 80.5% (112/139) were on no bone treatment on admission, 11.5% (16/139) were on calcium and vitamin D supplements, 1.4% (2/139) were taking vitamin D only and 1 patient taking calcium only, 2.1% (3/139) were taking Alendronate and 3.6% (5/139) were taking Denosumab. 19 patients gave a history of prior fracture: 73% (14/19) patients were on no treatment, 26% (5/19) were taking calcium and vitamin D supplements, 10.5% (2/19) were on Denosumab and 5% (1/19) was on Alendronate. On discharge, 74 patients were prescribed Denosumab, 39 were prescribed Alendronate and 3 received Zolendronic Acid. 83.5% (116/139) were discharged on bone protection compared to the 19.5% of patients admitted. Conclusions: The number of patients admitted with a hip fracture without bone protection was alarmingly high. By use of a hip fracture protocol and database we increased the number of patients being discharged on bone protection by 61%. Reference 1. Irish Hip Fracture database 2016
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